Tesaro, Inc. has signed an agreement with Amgen to gain exclusive worldwide rights for the development, manufacture, commercialization of small molecule inhibitors of Anaplastic Lymphoma Kinase (ALK). Tesaro plans to develop one or more compounds for oncology indications, including non-small cell lung cancer (NSCLC) in tumors that are ALK-positive. The agreement includes an upfront payment and potential future payments and royalties based on development and commercial milestones. Figures were no...